Expand Treatment Options for Complex Diseases
Substantial Cost Savings on Expensive Therapies
FDA-Approved, Safe and Effective Treatments
Support from FDA and Other Leading Medical Advisory Organizations
Biosimilar Master Class
Dr. Robert Rifkin and our team of expert clinical specialists and business advisors help you understand biosimilars from the U.S. Food and Drug Administration (FDA) perspective. While similar to biologic reference products, biosimilars have unique operational, clinical, and financial decision points critical to successfully implementing these therapies in your practice.
Learn MoreA Guide to Navigating Biosimilars
From 2017 to 2020, McKesson helped specialty providers save more than $386 million dollars through biosimilar adoption. As the biosimilar landscape continues to evolve, we can expect to see more biosimilar treatment options for more conditions. McKesson is here to help you navigate the landscape, identify economic opportunities for your practice and provide resources to physicians who are evaluating biosimilars for their patients.
Download Guide
ADDITIONAL READING
Biosimilar Perspectives from McKesson Experts
McKesson’s experts address the most important clinical, operational, and economical obstacles to overcome on the path to reimbursement.
An in depth look at the primary concerns of physicians when implementing biosimilars in their oncology and rheumatology practices.
Dr. Robert Rifkin, medical director of biosimilars for McKesson, gives an update on biosimilar education and reimbursement.
Dr. Robert Rifkin discusses the "perfect storm" for biosimilar marketing in a recent OncLive article.
A review of 14,000 individuals transitioned from a reference biologic medication to a biosimilar examines patient safety and treatment efficacy.
Overcoming Physician Barriers to Biosimilar Adoption in Clinics (PDF, 228 KB)
Omar Hafez shares how biopharmaceutical companies can learn how to overcome the clinical, operational, and economic barriers to biosimilar adoption.
Viewpoint
Biosimilar Endorsements From Major Medical Advisory Organizations
Read about the benefits of biosimilar growth from major Oncology and Rheumatology advisory bodies.
| (PDF, 648 KB)
Education
Stay up to date on new Medicare HCPCS codes and reimbursement guidance on biosimilars.
Visit the FDA biosimilar website for provider and patient-facing biosimilar resources. Topics include the latest FDA approvals, biosimilar 101 education, regulatory review and approval, interchangeability guidance and more.